About OSI Pharmaceuticals
OSI Pharmaceuticals is a Healthcare company based in Melville (United States) founded in 1983, and was acquired by Astellas Pharma in May 2010. Gene-targeted small molecule drugs for cancer and diabetes are developed. OSI Pharmaceuticals has completed 2 acquisitions, including Cell Pathways and EyeTech. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is OSI Pharmaceuticals, Inc. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
OSI Pharmaceuticals was focused on the development of drugs for the treatment of cancer and diabetes. Its approach utilized a comprehensive array of drug discovery and development technologies to target specific genes involved in human disease with novel small molecule drugs. Its advanced drug candidate was Tarceva, a small molecule inhibitor of the EGFR gene was in the market for the lung and pancreatic cancer. It was also developing Linsitinib, an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). In November 2001, it acquired oncology assets from Gilead for 200M in cash and stock. On June 9, 2010, OSI was acquired by Astellas Pharma for 4B.
- Headquarters Melville, United States
- Stage Acquired
- SectorsHealthcare
- Website osip.com
- Acquired by Astellas Pharma (May 2010)
- Legal Name Osi Pharmaceuticals, Inc.
- Investors
- Investments & AcquisitionsCell Pathways
& 1 more
- Acquired byAstellas Pharma
(May 2010)
Investors in OSI Pharmaceuticals
OSI Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Astellas Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Generic pharmaceuticals are developed, manufactured, and marketed worldwide. | 1923 | astellas.com | Chiba, Japan |
Investor details for OSI Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OSI Pharmaceuticals
OSI Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cell Pathways and EyeTech.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Biopharmaceuticals for treatment of Age related Macular degeneration | eyetech.com | Hanover, United States | 1996 | Aug 2005 | $685M | |
Small molecule-based drugs are developed for cancer treatment. | cellpathways.com | Horsham, United States | 1999 | Feb 2003 | $31M |
Complete acquisition details for OSI Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of OSI Pharmaceuticals
4 dated milestones of OSI Pharmaceuticals across 27 years, from founding to its latest funding, stage changes and deals.
- Founded OSI Pharmaceuticals is founded.
- Acquisition Acquires Cell Pathways.
- Acquisition Acquires EyeTech.
- Exit Acquired by Astellas Pharma.
Competitors of OSI Pharmaceuticals
OSI Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of OSI Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OSI Pharmaceuticals
Websites that share an audience with OSI Pharmaceuticals (osip.com).
Websites whose visitors overlap most with OSI Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| actelion.com | 100% | View details | |||
| thresholdpharm.com | 100% | View details | |||
| portola.com | 100% | View details | |||
| gilead.com | 85% | 576.5K | #103,109 | View details | |
erc.endocrinology-journals.org | erc.endocrinology-journals.org | 69% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for OSI Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as OSI Pharmaceuticals (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OSI Pharmaceuticals
OSI Pharmaceuticals was founded in 1983.
OSI Pharmaceuticals is headquartered in Melville, United States. It is registered at Melville, New York, United States.
OSI Pharmaceuticals was focused on the development of drugs for the treatment of cancer and diabetes. Its approach utilized a comprehensive array of drug discovery and development technologies to target specific genes involved in human disease with novel small molecule drugs. Its advanced drug candidate was Tarceva, a small molecule inhibitor of the EGFR gene was in the market for the lung and pancreatic cancer. It was also developing Linsitinib, an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). In November 2001, it acquired oncology assets from Gilead for 200M in cash and stock. On June 9, 2010, OSI was acquired by Astellas Pharma for 4B.
OSI Pharmaceuticals's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
OSI Pharmaceuticals has made 2 acquisitions, including Cell Pathways, and EyeTech.
OSI Pharmaceuticals has 1 investor. Key investors include Astellas Pharma.
OSI Pharmaceuticals operates through Osi Pharmaceuticals, Inc..
Yes. OSI Pharmaceuticals was acquired by Astellas Pharma in May 2010.